Cel-Sci (NYSEAMERICAN:CVM) Announces Earnings Results

Cel-Sci (NYSEAMERICAN:CVM) announced its quarterly earnings data on Tuesday. The company reported ($0.68) EPS for the quarter, FiscalAI reports.

Cel-Sci Stock Down 2.4%

NYSEAMERICAN:CVM traded down $0.12 on Tuesday, reaching $4.78. 15,956 shares of the stock traded hands, compared to its average volume of 69,211. The company has a market capitalization of $40.20 million, a price-to-earnings ratio of -0.49 and a beta of 0.77. Cel-Sci has a 12 month low of $1.98 and a 12 month high of $20.41. The company has a current ratio of 2.26, a quick ratio of 2.20 and a debt-to-equity ratio of 0.36. The company’s fifty day simple moving average is $5.43 and its 200 day simple moving average is $7.52.

Institutional Trading of Cel-Sci

Several hedge funds have recently bought and sold shares of CVM. State Street Corp grew its holdings in Cel-Sci by 9.9% during the fourth quarter. State Street Corp now owns 25,570 shares of the company’s stock worth $134,000 after acquiring an additional 2,300 shares during the period. Jane Street Group LLC purchased a new stake in Cel-Sci during the 4th quarter worth approximately $83,000. HRT Financial LP purchased a new stake in shares of Cel-Sci during the fourth quarter worth approximately $60,000. Renaissance Technologies LLC acquired a new position in Cel-Sci during the fourth quarter worth about $81,000. Finally, Geode Capital Management LLC grew its position in shares of Cel-Sci by 30.3% in the fourth quarter. Geode Capital Management LLC now owns 79,183 shares of the company’s stock valued at $417,000 after purchasing an additional 18,432 shares in the last quarter. Hedge funds and other institutional investors own 12.08% of the company’s stock.

Cel-Sci Company Profile

CEL-SCI Corporation is a biotechnology company focused on the development of immunotherapy products to treat cancer and infectious diseases. Founded in 1983 and headquartered in Vienna, Virginia, the company applies its proprietary LEAPS® (Ligand Epitope Antigen Presentation System) and Multikine® immunotherapy platforms to stimulate the body’s immune response against disease. CEL-SCI operates as a clinical-stage enterprise, working to translate immunological insights into therapeutic candidates.

The company’s lead product candidate, Multikine (leukineferon), is an investigational immunotherapy designed to enhance the immune system’s ability to attack head and neck cancer cells.